Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one

American Journal of Hematology

Volumn 51, Issue 2, 1996, Pages 152-157

  Tisdale, John F ^a   Figg, William D ^b   Reed, Eddie ^b   McCall, Natalie A ^b   Alkins, Brenda R ^b   Horne III, McDonald K ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immune; Suramin; Thrombocytopenia

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G; SURAMIN;

ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLATELET AGGREGATION; PROSTATIC NEOPLASMS; SURAMIN; THROMBOCYTOPENIA;

EID: 0030052260     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199602)51:2<152::AID-AJH10>3.0.CO;2-K     Document Type: Article

References (18)

1. Horne MK, Wilson OJ, Cooper M, Gralnick HR, Myers CE: The effect of suramin on laboratory tests of coagulation. Thromb Haemost 67:434, 1992.
2. Horne MK, Stein CA, LaRocca RV, Myers CE: Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 71:273, 1988.
3. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499, 1989
4. La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC: Suramin-induced polyneuropathy. Neurology 40:954, 1990.
5. Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE: Anaphylactoid reaction with suramin. Pharmacotherapy 13:656, 1993 (published erratum in Pharmacotherapy 14:125, 1994).
6. O'Donnell BP, Dawson NA, Weiss RB, Myers CE, James WD: Suramin-induced skin reactions. Arch Dermatol 128:75, 1992.
7. Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O: Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 74:1612, 1994.
8. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill P, Volberding PA, Poiesz BJ: Surammin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA 258:1347, 1987.
9. LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Myers CE: Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am 18:123, 1991.
10. Eisenberger MA, Reyno LM, Jodrell DI, Simbaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH. Jacobs SC, Egorin MJ: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. JNCI 85:611, 1993 (published erratum in JNCI 86:639, 1994).
11. Seidman AD, Schwartz M, Reich L, Scher HT: Immune-mediated thrombocytopenia secondary to suramin. Cancer 71:851, 1993.
12. Supko JG, Malspeis L: A rapid isocratic HPLC assay of suramin in human plasma. J Liq Chromatogr 13:727, 1993.
13. De Bruijn EA, Pattyn G, Denis L, Mahler C, Van Oosterom AT, Desmedt E: Therapeutic drug monitoring of suramin and protein binding. J Liq Chromatogr 14:3719, 1991.
14. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27, 1986.
15. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH: Recent research on the biological activity of suramin. Pharmacol Rev 45:177, 1993
16. Shulman NR, Leissinger CA, Hotchkiss AJ, Kautz CA: The nonspecific nature of platelet-associated IgG. Trans Assoc Am Physicians 95:213, 1982.
17. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232, 1994.
18. Buzdar AU, Fraschini G, Blumenschein GR: Hematologic adverse effects of aminoglutethimide. Ann Intern Med 100:159, 1984.